Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach Robert Frank Cornell, Parameswaran Hari, William R. Drobyski Biology of Blood and Marrow Transplantation Volume 21, Issue 12, Pages 2061-2068 (December 2015) DOI: 10.1016/j.bbmt.2015.08.030 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Engraftment syndrome encompasses a spectrum of ASCT-associated syndromes that vary in degrees of severity. PERDS indicates periengraftment respiratory distress syndrome; CLS, capillary leak syndrome. Biology of Blood and Marrow Transplantation 2015 21, 2061-2068DOI: (10.1016/j.bbmt.2015.08.030) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Hypothetical mechanisms of ES. Proposed stages and severities of ES after ASCT are modeled. Predicted cytokine and leukocyte involvement is shown for each stage. Neutrophil and T cell engraftments are complete by days 14 and 56, respectively. TNF indicates tumor necrosis factor; Mac, macrophage; N, neutrophil; DC, dendritic cell; CD4, helper T cell; CD8, cytotoxic T cell; B, B cell; NE, normal epithelium. Biology of Blood and Marrow Transplantation 2015 21, 2061-2068DOI: (10.1016/j.bbmt.2015.08.030) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Our management approach to ES. IST indicates immunosuppressive therapy. Biology of Blood and Marrow Transplantation 2015 21, 2061-2068DOI: (10.1016/j.bbmt.2015.08.030) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions